ABNX — Abionyx Pharma SA Cashflow Statement
0.000.00%
- €42.31m
- €41.83m
- €4.55m
Annual cashflow statement for Abionyx Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.89 | -5.82 | -4.21 | -3.52 | -4.38 |
Depreciation | |||||
Non-Cash Items | -0.865 | 0.755 | 0.615 | -0.871 | 0.64 |
Other Non-Cash Items | |||||
Changes in Working Capital | 2.13 | -1.74 | 0.097 | 0.538 | -0.028 |
Change in Prepaid Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -0.599 | -6.69 | -3.36 | -3.7 | -3.63 |
Capital Expenditures | -0.148 | -0.166 | -0.175 | -0.13 | -0.076 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.023 | 1.5 | — | — | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Cash from Investing Activities | -0.125 | 1.34 | -0.175 | -0.13 | -0.076 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.55 | 3.97 | -0.194 | 3.89 | 2.84 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.823 | -1.38 | -3.73 | 0.058 | -0.866 |